Studi Penggunaan Deksametason Pada Pasien Covid-19 Derajat Berat Dengan Komorbid Diabetes Mellitus (Penelitian di Rumah Sakit Bhayangkara H.S. Samsoeri Mertojoso Surabaya)

• Main Author: Anissah Insyirah Idris, '-
• Format: Theses and Dissertations NonPeerReviewed
• Language: Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian; Indonesian
• Published: 2021
• Subjects: RS200-201 Pharmaceutical dosage forms
• Online Access: https://repository.unair.ac.id/112380/1/1.%20JUDUL.pdf; https://repository.unair.ac.id/112380/2/2.%20ABSTRACT.pdf; https://repository.unair.ac.id/112380/3/3.%20DAFTAR%20ISI.pdf; https://repository.unair.ac.id/112380/4/4.%20BAB%20I%20PENDAHULUAN.pdf; https://repository.unair.ac.id/112380/5/5.%20BAB%20II%20TINJAUAN%20PUSTAKA.pdf; https://repository.unair.ac.id/112380/6/6.%20BAB%20III%20KERANGKA%20KONSEP.pdf; https://repository.unair.ac.id/112380/7/7.%20BAB%20IV%20METODE%20PENELITIAN.pdf; https://repository.unair.ac.id/112380/8/8.%20BAB%20V%20HASIL%20PENELITIAN%20DAN%20PEMBAHASAN.pdf; https://repository.unair.ac.id/112380/9/9.%20BAB%20VI%20KESIMPULAN%20DAN%20SARAN.pdf; https://repository.unair.ac.id/112380/10/10.%20DAFTAR%20PUSTAKA.pdf; https://repository.unair.ac.id/112380/11/11%20LAMPIRAN.pdf; https://repository.unair.ac.id/112380/12/KESEDIAAN%20PUBLIKASI.pdf; https://repository.unair.ac.id/112380/; http://www.lib.unair.ac.id
• Institution: Universitas Airlangga

Coronavirus Disease 2019 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 that has never been found in humans before. Diabetes mellitus (DM) is a comorbid that becomes as major risk factors that can worsen the symptoms and increase the severity in COVID-19’s patients. Dexamethasone is used as anti-inflammatory agent to treat inflammation caused by cytokine storms. However, dexamethasone can increase blood glucose concentrations in COVID-19 patients with comorbid DM due to glucocorticoids effects. This study aims to determine the effectiveness and how it regulates blood glucose in severe COVID-19 patients with comorbid DM who use dexamethasone. This study is a descriptive observational study using retrospective data from Bhayangkara HS Samsoeri Mertojoso Hospital Surabaya from September 2020 - February 2021. The results of the study on 27 patients who met the inclusion criteria showed that administering Dexamethasone (1 x 6 mg) IV was effective in severe COVID-19’s patient with comorbid DM based on length of hospitalization of 13 days, 14 days, and 12 days, respectively; improvement of clinical condition of oxygen saturation by 91%, 100%, 100%; RT-PCR/Rapid Ag became negative 74%, 100%, 100%; and improvement of chest x-ray results by 83%, 33%, 100%, respectively. The glucocorticoid effect of dexamethasone in comorbid DM patients is regulated by administration of long-acting insulin, rapid-acting insulin and oral anti-diabetic. Based on the description above, the use of dexamethasone therapy for severe COVID-19 patients with comorbid DM is already appropriate with the patient's clinical condition and literature.